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ABSTRACT
Introduction Cochrane Eyes and Vision (CEV) is an 
international network of individuals working to prepare, 
maintain and promote access to systematic reviews of 
interventions to treat, prevent or diagnose eye diseases or 
vision impairment. CEV plans to undertake a priority setting 
exercise to identify systematically research questions 
relevant to our scope, and to formally incorporate input 
from a wide range of stakeholders to set priorities for new 
and updated reviews.
Methods and analysis The scope of CEV is broad and our 
reviews include conditions that are common and have a 
high global disease burden, for example, cataract and dry 
eye disease, and conditions that are rare but have a high 
impact on quality of life and high individual cost such as 
eye cancer. We plan to focus on conditions prioritised by 
WHO during the development of the Package of Eye Care 
Interventions. These conditions were selected based on 
a combination of data on disease magnitude, healthcare 
use and expert opinion. We will identify priority review 
questions systematically by summarising relevant data on 
research in Eyes and Vision from a range of sources, and 
compiling a list of 10–15 potential review questions (new 
and/or updates) for each condition group. We will seek 
the views of external and internal stakeholders on this list 
by conducting an online survey. Equity will be a specific 
consideration.
Ethics and dissemination The study has been approved 
by the ethics committee of the London School of Hygiene 
& Tropical Medicine. We will disseminate the findings 
through Cochrane channels and prepare a summary of the 
work for publication in a peer- reviewed journal.
INTRODUCTION
Cochrane Eyes and Vision (CEV) is an inter-
national network of individuals working to 
prepare, maintain and promote access to 
systematic reviews of interventions to treat or 
prevent eye diseases or vision impairment. We 
also conduct systematic reviews of the accu-
racy of diagnostic tests for common ocular 
diseases or conditions.
CEV was established in 1997.1 We have used 
a variety of priority setting approaches over 
the years, including working with guideline 
panels2 3 and participating in a James Lind 
Alliance Priority Setting Partnership for 
Sight Loss and Vision,4 but we have largely 
relied on review author teams to suggest 
review titles. These titles are evaluated by 
the editorial base and our network of editors 
(see https:// eyes. cochrane. org/ about- cev 
for list) to assess whether they would form a 
suitable review question, ensuring no overlap 
with current Cochrane systematic reviews or 
with high quality, recently published, non- 
Cochrane systematic reviews. We consider 
the following criteria when prioritising review 
titles suggested by review author teams:
 ► Does the proposed new review (or review 
update) address an important clinical 
uncertainty? By ‘important’ we mean that 
the review topic is one that patients, clini-
cians, policymakers or the public would 
like to have answered, that is, is important 
to them. A ‘clinical uncertainty’ reflects 
the situation where there is evidence of 
variation in practice or differing opin-
ions as to the best or most effective 
intervention.
 ► Will a Cochrane Review (new review 
or review update) at this point in time 
resolve this clinical uncertainty? Largely 
this means that we aim to prioritise 
reviews that will include a number of 
Strengths and limitations of this study
 ► This is a systematic assessment of priority questions 
for Cochrane Eyes and Vision systematic reviews.
 ► We will seek global input, considering questions ir-
respective of location or setting.
 ► The study will draw on a wide range of stakeholders 
and resources.
 ► The focus will be mainly on new reviews and topics 
but we will also consider potential review updates.
 ► The conduct of an online survey will limit the amount 
of discussion possible.
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reasonably large and robust studies. However, some-
times we judge that identifying a gap in the evidence 
is also important, if identifying that gap will be likely 
to lead to further intervention studies.
 ► To what extent would resolving this clinical uncer-
tainty reduce the magnitude of vision impairment 
and eye health disorders? This is clearly a subjective 
judgement but takes into account knowledge of the 
magnitude of the eye disease or vision impairment 
and anticipated effect, or cost- effectiveness, of the 
intervention.
 ► To what extent would resolving this clinical uncer-
tainty reduce inequalities/disparities in the magni-
tude of disease or access to care for vision impairment 
or eye health disorders? Ideally, we would prioritise 
reviews and interventions that address inequity.
This approach identifies titles that are important to 
clinicians and researchers but may be less likely to identify 
questions relevant to other stakeholders such as patients, 
public and policy- makers. It is also likely to result in focus 
on higher- income settings, with high research capacity 
and less emphasis on equity- relevant titles. A recent 
review highlighted the lack of equity- relevant Cochrane 
Reviews on cataract .5
CEV plans to undertake a priority setting exercise to 
assess systematically the nature and extent of research 
questions relevant to our scope, and to formally incorpo-
rate input from a wide range of stakeholders to set priori-
ties for new and updated reviews. This document outlines 
the protocol for a priority setting exercise to identify 
important review questions. It is informed by guidance 
prepared by Cochrane on setting review priorities6 and 
by the REporting guideline for PRIority SEtting of health 
research framework for reporting priority setting of 
health research.7 Equity will be a specific consideration 
in the priority setting process. As part of this process, 
we will also be informed by the work of other organisa-
tions undertaking priority setting activities in the field of 
Eyes and Vision, including the recent Grand Challenges 
in global eye health undertaken as part of the Lancet 
Global Health Commission on Global Eye Health8 and the 
Package of Eye Care Interventions (PECI) being devel-
oped by WHO.9 10
AIMS
The CEV Priority Setting Exercise aims to generate and 
publicise a list of priority topics, for both new and updated 
reviews, ensuring involvement of our main stakeholders.
METHODS
Context and scope
The scope of CEV is global and includes conditions that 
are common and have a high global disease burden, for 
example, cataract and dry eye disease, and conditions 
that are rare but have a high impact on quality of life and 
high individual cost such as eye cancer. The intended 
beneficiaries of our work are people making health-
care decisions for eye healthcare. CEV reviews primarily 
address questions relevant to clinical research (treatment, 
diagnosis, prognosis) but also potentially cover public 
health, health services and implementation research.
We plan to focus on the list set out in box 1 adapted 
from conditions prioritised by WHO as part of the devel-
opment of the PECI. These conditions have been selected 
based on a combination of data on disease magnitude, 
healthcare use and expert opinion.
Governance
To advise on the scope of the exercise, we set up a 
steering group including ophthalmologists, optome-
trists, orthoptists, ophthalmic nurses and relevant profes-
sional bodies, patient organisations, experienced clinical 
editors, systematic review methodologists and informa-
tion specialists of CEV; it includes participants from high 
and low- income settings. Members of the team have been 
involved in previous priority setting exercises.
Stakeholders and participants
Any person with an interest in healthcare decision- making 
relevant to eye healthcare is eligible to take part. This 
includes patients, caregivers, the general public, health 
professions, researchers, policy- makers, government and 
non- government organisations, and industry. We will 
actively seek out potential stakeholders using the exper-
tise of the steering group to identify relevant stakeholder 
organisations and individuals globally in their field. We 
will then write to each stakeholder organisation or indi-
vidual identified by the steering group to invite them to 
take part in the online survey and to identify further rele-
vant stakeholders (snowballing).
Identifying research questions
For each condition, we will undertake the following steps 
in order to identify priority questions for each condition, 
consulting with the steering group as needed (figure 1):
1. Identify and summarise relevant data on research in 
eyes and vision. We plan to use the following sources:
 ► Global policy reports.
 ► Other research prioritisation and roadmaps.







7. Disorders of eye movement.
8. Infectious and inflammatory diseases.
9. Ocular trauma.
10. Ocular surface disorders.
11. Disorders of the eyelid and lacrimal system.
12. Eye cancer.
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 ► Guidelines.
 ► CEV systematic reviews.
 ► CEV@US Project Database of Systematic Reviews in 
Eyes and Vision.11
 ► Intervention studies on The Cochrane Library 
(CENTRAL).
We will identify global policy reports and other research 
prioritisation exercises (eg, James Lind Alliance Priority 
Setting Process in Sight Loss and Vision4) from searching 
academic databases and contact with our steering group. 
One member of the research team will scrutinise these 
reports for identified research questions. We will iden-
tify high- quality guidelines from the process followed by 
WHO during the development of the PECI. We will rank 
current CEV reviews according to impact using Altmetric 
and access statistics provided by the publisher. The top 
Figure 1 Flow chart of study process. CEV, Cochrane Eyes and Vision.
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20% of reviews identified by this process, that is, reviews 
with highest Altmetric score and/or access statistics will 
be eligible for the priority setting process. We will search 
The Cochrane Library for studies relevant to Eyes and 
Vision published within the last 3 years, or on a trials regis-
ters. One author (IG) will scan these reports to identify 
new potential review titles, that is, PICOs identified in two 
or more studies, that have not already been addressed 
in Cochrane Reviews. Search strategies are in the online 
supplemental appendix 1.
(2)Using the information from (1) we will prepare a 
list of potential review topics, removing duplicates as 
needed or merging/combining similar questions. This 
list will be reviewed by the Steering Group after it has 
been refined by removing questions where:
 ► High quality, current systematic reviews exist and new 
trials are either unlikely to have been done, or if they 
have been done, are unlikely to change the conclu-
sions of the review. We will check for Cochrane Reviews 
and non- Cochrane high quality systematic reviews in 
the database maintained by CEV@US project.
 ► Topic is beyond scope because either it does not 
address a condition of interest (box 1) or it does not 
address a relevant clinical question.
 ► Question is unclear or ill defined or cannot be 
answered by either an intervention, diagnostic test 
accuracy, prognostic or scoping review.
Conducting the priority setting exercise
We will seek the views of external and internal stake-
holders on the list generated in (2) by conducting an 
online survey using Qualtrics software (Qualtrics, Provo, 
Utah, USA, available at www. qualtrics. com). We aim to 
present a list of 10–15 potential review questions (new 
and/or updates) for each condition group in this online 
survey.
We will identify key stakeholders, initially by consulta-
tion with the Steering Group, but also including further 
‘snowballing’, that is, asking stakeholders to identify other 
relevant stakeholders. We will request information on key 
research needs. The categories of stakeholders that we 
will consider include but will not be restricted to:
 ► Patients and public.
 ► Providers, purchasers and payers.
 ► Policy- makers.
 ► Principal investigators and research funders.
Participants will be identified through two methods: 
advertising and direct invitation. We will advertise 
through social media (eg, Twitter, Facebook and 
Cochrane channels) and within academic (eg, Alumni 
networks, Community Eye Health Bulletin,) clinical 
and professional networks (eg, ophthalmological, 
optometric and orthoptic societies). We will inform the 
stakeholders identified above, and ask members of the 
Steering Group, to circulate within their networks. We 
will invite some participants directly to take part and will 
ensure that these invitations are balanced with respect 
to gender, location (working/living in a high- income or 
lower- income setting) and profession (clinician, patient, 
policy- maker). We will approach Cochrane contributors 
and other contacts we consider potentially interested to 
contribute and will draw on the previous participants of 
the Grand Challenges for Eye Health (names available in 
public domain). We will not perform any other formal 
process for ensuring balance, but we will collect limited 
information on respondents (gender, location, profes-
sion) and how they were informed about the survey so 
that we understand who has responded.
We will conduct a two- round process. In the first round, 
we will present questions separately for each condition 
and ask the participants to rank in order of priority, that 
is, which reviews or review updates should CEV complete 
first, in the opinion of the respondent. There will be 
space for the participant to add additional questions that 
have not been included in the presented list. We will be 
seeking questions relevant to intervention reviews, diag-
nostic test accuracy reviews, prognostic reviews or scoping 
reviews only. Within 4 weeks, we will present a second 
round, in which the top five questions for each condi-
tion will be presented, along with any additional new 
questions identified during the course of the first round. 
Participants will be asked to score each review question 
presented according to the following criteria (4- point 
scale 1=definitely not/no extent, 2=possibly not/small 
extent, 3=possibly yes/moderate extent, 4=definitely yes/
large extent):
 ► Does the proposed new review (or review update) 
address an important clinical uncertainty?
 ► Will a Cochrane Review (new review or review update) 
at this point in time resolve this clinical uncertainty?
 ► To what extent would resolving this clinical uncer-
tainty reduce the magnitude of vision impairment and 
eye health disorders?
 ► To what extent would resolving this clinical uncer-
tainty reduce inequalities/disparities in (ie, have 
an equalising effect of) the magnitude of disease or 
access to care for vision impairment or eye health 
disorders?
Following these two rounds, for each condition, we will 
identify the three questions with the highest average score. 
Each question will be structured in the PICO (Participants, 
Interventions, Comparator, Outcome) format, adapted 
for other contexts, for example, diagnosis, prognosis as 
necessary. As part of this process, we will be guided by the 
quantitative and qualitative results of these surveys but, to 
align with our commitment to widen the inclusion and 
equity- relevance of CEV reviews, we will include at least 
one question relevant to lower income settings. We will 
also report ranking of review question priorities by loca-
tion and stakeholder background to assess the extent to 
which priorities within different groups differ.
Equity
We will consider equity as part of this process, drawing 
on methods developed by the Campbell and Cochrane 
Equity Methods group (https:// methods. cochrane. org/ 
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equity/ about- us). One member of the Steering Group 
has a special interest in equity. Our main approach will be 
to ensure that we have as wide a participation as possible 
(see above for details). We are taking the opportunity to 
draw on current partnerships with global initiatives to 
ensure priorities are informed by representation from 
low- income and middle- income countries. We will also 
prioritise questions that the survey participants have 
considered would reduce inequalities (last question 
above).
Patient and public involvement
Patient and public involvement will be through the 
Steering Group and by contributing to the priority setting 
exercise.
ETHICS AND DISSEMINATION
The study has been approved by the ethics committee 
of the London School of Hygiene & Tropical Medicine. 
Please see online supplemental appendix 2 for informa-
tion to be given to participants in the online survey. All 
data collection will be electronic. We will disseminate 
the findings through Cochrane channels and prepare a 
summary of the work for publication in a peer- reviewed 
journal.
We will publish, through relevant Cochrane channels, 
our intention to conduct a priority setting process so that 
external and internal stakeholders may be involved.
We plan to:
 ► Document our plans for priority setting including 
stakeholder engagement, methods and criteria.
 ► Document the implementation of the priority- setting 
process on our website (including link to relevant 
network portal) and in an academic publication.
 ► Publish a list of priority topics on the CEV website.
 ► Develop a plan for how the priority topics will be 
delivered.
 ► Provide feedback to stakeholders involved, including 
notification when priority reviews are published.
Currency/timeframe
We plan to complete the Priority Setting Exercise during 
June to December 2021 and repeat within 3–5 years.
Evaluation and feedback
Written feedback will be given to all participants in the 
process who have supplied an email address, including 
a plain language account of the process and outcome of 
the process. All participants will be acknowledged in the 
final report (with permission).
We will evaluate the priority setting process by asking 
participants to complete a questionnaire collecting quan-
titative data and qualitative information on the following 
outcomes.
Short-term evaluation
 ► Did the priority setting process meet Cochrane manda-
tory and desirable criteria for governance, stakeholder 
engagement, documentation and dissemination?
 ► Was the process complete within the prespecified 
time frame?
 ► Was the process completed without using excessive 
CEV staff time?
 ► Gather feedback from stakeholders via questionnaire
 – What did stakeholders like about the process?
 – What did stakeholders want to improve about the 
process?
 ► Gather feedback from CEV staff
 – What did CEV staff like about the process?
 – What did CEV staff want to improve about the 
process?
Long-term evaluation
1. Were the resultant reviews produced in a timely 
manner?
2. Were the resultant reviews relevant/important? For ex-
ample, did they have higher Altmetric/impact score?
3. Were the reviews used in guidelines or other policy 
documents?
Other considerations
 ► Equity—how have the results improved equity? Have 
any of the reviews considered most relevant for equity 
in the process above been undertaken?
 ► Has there been an increase in authors from low- 
income and middle- income settings?
CONCLUSION
A systematic and transparent approach to identifying 
review questions, informed by credible evidence, and 
reaching out to a broader group of people to assess prior-
ities will help CEV establish which reviews need to be 
prioritised in the next 3–5 years.
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